Literature DB >> 29463166

Clinicopathological indicators of survival among patients with pulmonary carcinoid tumor.

Tiina Vesterinen1,2, Sanna Mononen3, Kaisa Salmenkivi4, Harri Mustonen5, Jari Räsänen, Jarmo A Salo, Ilkka Ilonen3, Aija Knuuttila6, Caj Haglund5,7, Johanna Arola1.   

Abstract

BACKGROUND: Pulmonary carcinoids (PC) are rare malignant neoplasms that cover approximately 1% of all lung cancers. PCs are classified by histological criteria as either typical (TC) or atypical (AC). Histological subtype is the most studied prognostic factor. The aim of this study was to evaluate if other tissue or clinical features are associated with patient outcomes.
MATERIAL AND METHODS: We retrospectively reviewed clinical records of 133 PC patients who underwent operation in the Helsinki University Hospital between 1990 and 2013. Tissue specimens were re-evaluated, processed into tissue microarray format and stained immunohistochemically with serotonin, calcitonin, adrenocorticotropic hormone (ACTH), thyroid transcription factor-1 (TTF-1) and Ki-67. Survival and risk analyses were performed.
RESULTS: Based on histology, 75% (n = 100) of the tumors were TCs and 25% (n = 33) ACs. TCs had higher 10-year disease-specific survival (DSS) rate than ACs (99% (95% CI, 93-100%) for TCs vs. 82% (95% CI, 61-92%) for ACs). Hormonally active tumors expressing serotonin, calcitonin or ACTH were noted in 53% of the specimens but hormonal expression was not associated with DSS. TTF-1 was positive in 78% of the specimens but was not associated with DSS. Ki-67 index varied between <1% and 15%. Ki-67 ≥ 2.5% was associated with shorter DSS (p = .004). The presence of metastatic disease (p = .001), tumor size ≥30 mm (p = .021) and atypical histology (p = .011) were also associated with disease-specific mortality.
CONCLUSIONS: We conclude that PCs are uncommon tumors. When resected, the long-term survival is in general favorable. In this consecutive, single-institution cohort of patients, presence of metastatic disease, tumor size, histological subtype and Ki-67 index were associated with shorter disease-specific survival. As TC and AC have different clinical behaviors, the correct tumor classification at the time of diagnosis is a necessity.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29463166     DOI: 10.1080/0284186X.2018.1441543

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  10 in total

Review 1.  ACTH-producing tumorlets and carcinoids of the lung: clinico-pathologic study of 63 cases and review of the literature.

Authors:  Stefano La Rosa; Marco Volante; Silvia Uccella; Roberta Maragliano; Ida Rapa; Nicola Rotolo; Frediano Inzani; Alessandra Siciliani; Pierluigi Granone; Guido Rindi; Lorenzo Dominioni; Carlo Capella; Mauro Papotti; Fausto Sessa; Andrea Imperatori
Journal:  Virchows Arch       Date:  2019-07-01       Impact factor: 4.064

2.  Clinicopathological, Oncogenic, and 18F-FDG PET/CT Features of Primary Pulmonary Carcinoid in Resection Specimens.

Authors:  Yun Chen; Yun Dong; Jingyun Shi; Long Zhao
Journal:  Contrast Media Mol Imaging       Date:  2022-06-15       Impact factor: 3.009

3.  Automated assessment of Ki-67 proliferation index in neuroendocrine tumors by deep learning.

Authors:  Tiina Vesterinen; Jenni Säilä; Sami Blom; Mirkka Pennanen; Helena Leijon; Johanna Arola
Journal:  APMIS       Date:  2021-11-22       Impact factor: 3.428

4.  Assessment of the prognostic factors in patients with pulmonary carcinoid tumor: a population-based study.

Authors:  Yiwei Huang; Xiaodong Yang; Tao Lu; Ming Li; Mengnan Zhao; Xingyu Yang; Ke Ma; Shuai Wang; Cheng Zhan; Yu Liu; Qun Wang
Journal:  Cancer Med       Date:  2018-05-07       Impact factor: 4.452

5.  PD-1 and PD-L1 expression in pulmonary carcinoid tumors and their association to tumor spread.

Authors:  Tiina Vesterinen; Teijo Kuopio; Maarit Ahtiainen; Aija Knuuttila; Harri Mustonen; Kaisa Salmenkivi; Johanna Arola; Caj Haglund
Journal:  Endocr Connect       Date:  2019-08-01       Impact factor: 3.335

6.  Prognostic value of the immunohistochemistry markers CD56, TTF-1, synaptophysin, CEA, EMA and NSE in surgically resected lung carcinoid tumors.

Authors:  Vasiliki Epameinondas Georgakopoulou; Eleftherios Zygouris; Christos Damaskos; Aikaterini Pierrakou; Petros Papalexis; Nikolaos Garmpis; Aikaterini Aravantinou-Fatorou; Serafeim Chlapoutakis; Evangelos Diamantis; Christos Nikokiris; Aikaterini Gkoufa; Pagona Sklapani; Nikolaos Trakas; Jim Janinis; Demetrios A Spandidos; Jubrail Dahabreh
Journal:  Mol Clin Oncol       Date:  2021-12-14

7.  Utility of KI-67 as a prognostic biomarker in pulmonary neuroendocrine neoplasms: a systematic review and meta-analysis.

Authors:  Salma Naheed; Chloe Holden; Lulu Tanno; Linda Pattini; Neil W Pearce; Bryan Green; Eleanor Jaynes; Judith Cave; Christian H Ottensmeier; Giuseppe Pelosi
Journal:  BMJ Open       Date:  2022-03-03       Impact factor: 2.692

8.  Hierarchical identification of a transcriptional panel for the histological diagnosis of lung neuroendocrine tumors.

Authors:  Juxuan Zhang; Jiaxing Deng; Xiao Feng; Yilong Tan; Xin Li; Yixin Liu; Mengyue Li; Haitao Qi; Lefan Tang; Qingwei Meng; Haidan Yan; Lishuang Qi
Journal:  Front Genet       Date:  2022-08-29       Impact factor: 4.772

9.  Angioside: The role of Angiogenesis and Hypoxia in Lung Neuroendocrine Tumours According to Primary Tumour Location in Left or Right Parenchyma.

Authors:  Anna La Salvia; Raffaella Carletti; Monica Verrico; Tiziana Feola; Giulia Puliani; Massimiliano Bassi; Franz Sesti; Angelina Pernazza; Rossella Mazzilli; Giuseppe Lamberti; Alessandra Siciliani; Massimiliano Mancini; Chiara Manai; Federico Venuta; Mohsen Ibrahim; Silverio Tomao; Giulia D'Amati; Cira Di Gioia; Elisa Giannetta; Federico Cappuzzo; Antongiulio Faggiano
Journal:  J Clin Med       Date:  2022-10-09       Impact factor: 4.964

10.  Development and Validation of an Individualized Nomogram for Predicting Overall Survival in Patients With Typical Lung Carcinoid Tumors.

Authors:  Shenghua Dong; Jun Liang; Wenxin Zhai; Zhuang Yu
Journal:  Am J Clin Oncol       Date:  2020-09       Impact factor: 2.787

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.